# TDM of Generic Lopinavir/Ritonavir 200/50 mg

> **NCT00802334** · PHASE2 · COMPLETED · sponsor: **The HIV Netherlands Australia Thailand Research Collaboration** · enrollment: 70 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** generic lopinavir/ritonavir

## Key facts

- **NCT ID:** NCT00802334
- **Lead sponsor:** The HIV Netherlands Australia Thailand Research Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802334, "TDM of Generic Lopinavir/Ritonavir 200/50 mg". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00802334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*